Stemline Therapeutics (STML) Reports Q2 Loss of $0.66/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. TMUS
7. SPY
8. CVS
9. UNH
10. VZ

Go back to Stemline Therapeutics (STML) Reports Q2 Loss of $0.66/Share

Stemline Therapeutics Reports Second Quarter 2017 Financial Results

August 8, 2017 7:00 AM EDT

NEW YORK, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today financial results for the quarter ended June 30, 2017. The Company also reviewed recent clinical and regulatory events, and outlined key upcoming milestones:

SL-401 In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

The SL-401 pivotal Phase 2 trial enrolled 45 BPDCN patients in Stages 1, 2 and 3. Stage 3 was prospectively designed to support potential registration.During the quarter, we presented updated data from Stages 1 and 2 of... More